Accompanying and Prevention Therapy of Undesirable Reactions in Patients with Pulmonary Tuberculosis

Objective of the study -to evaluate the e ectiveness of the use of the drug Phosphogliv for the accompanying and prevention therapy of adverse reactions in patients with newly diagnosed pulmonary tuberculosis with con rmed drug sensitivity to mycobacterium tuberculosis. Material and methods. Adverse reactions were studied when Phosphogliv was prescribed in 76 patients and in the comparison group in 68 patients who received Essentiale forte N, all patients were on chemotherapy regimen I. Results. A er 2 months in the main group, mild adverse reactions (according to the international scale STSAE), had 16 (21.1%) patients (95% CI 12.5-31.9), moderate severity -8 (10.5%) patients ; in the comparison group -mild -17 (25.0%) patients (95% CI 15.3-37.0), moderate -15 (22.1%) patients (95% CI 12.9-33.7), 4 (5.9%) patients (95% CI 1.6-14.4) had severe disorders. A er 4 months of treatment in the main group, mild adverse reactions were detected only in 8 patients, in the comparison . During treatment, both a er 2 and 4 months, in the comparison group, the state of the free radical oxidation system indicated a continuing high activity. In the main group a er 2 months the indicators returned to normal. In patients of the main group, higher e cacy of treatment of pulmonary tuberculosis was established compared with the comparison group: a er 4 months of treatment, the cavities preserved in 6. 6% (2.2-14.7) and 25.0% (15.3-37.0), respectively (p < 0.05).